RESUMEN
Seafloor methane emissions can affect Earth's climate and ocean chemistry. Vast quantities of methane formed by microbial decomposition of organic matter are locked within gas hydrate and free gas on continental slopes, particularly in large areas with high sediment accumulations such as deep-sea fans. The release of methane in slope environments has frequently been associated with dissociation of gas hydrates near the edge of the gas hydrate stability zone on the upper slope, with discharges in greater water depths less understood. Here we show, using data from the Rio Grande Cone (western South Atlantic), that the intrinsic, gravity-induced downslope collapse of thick slope sediment accumulations creates structures that serve as pathways for gas migration, unlocking methane and causing seafloor emissions via giant gas flares in the water column. The observed emissions in the study region (up to 310 Mg year-1) are three times greater than estimates for the entire US North Atlantic margin and reveal the importance of collapsing sediment accumulations for ocean carbon cycling. Similar outgassing systems on the Amazon and Niger fans suggest that gravity tectonics on passive margins is a common yet overlooked mechanism driving massive seafloor methane emissions in sediment-laden continental slopes.
RESUMEN
The increasing demand for the elemental determination of petrochemical samples by inductively coupled plasma techniques requires the development of suitable sample preparation methods that permit high sample throughput and are in accordance with green chemistry recommendations. For this aim, the development of microwave-induced combustion (MIC) method has been attempted to completely digest petroleum coke samples and address quantitative determination of elements, such as Ag, Al, Ba, Ca, Cd, Co, Cu, Fe, Mg, Mn, Mo, Na, Ni, Pb, Sr, V and Zn, by inductively coupled plasma optical emission spectrometry (ICP OES). A sequential procedure to evaluate the sample mass and the solution to retain the analytes quantitatively was first conducted. Satisfactory results were obtained (residual carbon content in final solutions was lower than 0.5%) by digesting 400 mg of samples using 20 bar of oxygen and analytes were quantitatively retained in a dilute acid solution such as 4.2 mol L-1 HNO3. An agreement better than 87% was achieved using certified reference materials and the performance of the proposed method was also compared to that of the standard procedure recommended by the American Society of Testing and Materials ASTM D 5600. Despite both methods producing similar results, the proposed method by MIC was much simpler, offered a higher sample throughput and the digests were compatible with ICP OES measurements avoiding interferences in the determination step compared the ASTM D 5600 method. These results clearly demonstrated that the proposed MIC method in combination with ICP OES could be a promising alternative to obtain quantitative information about the elemental composition of petroleum coke.
Asunto(s)
Coque , Petróleo , Digestión , Espectrometría de Masas/métodos , MicroondasRESUMEN
Zileuton is an inhibitor of the 5-lipoxygenase enzyme that transforms essential fatty acid (EFA) substrates into leukotrienes (LTB4, LTC4, LTD4 and LTE4), but little is known about the use of this drug in teleost fish. Therefore, the objective of this study was to evaluate the clinical safety of treatments with 2,25 mg and 4,50 mg of zileuton/Kg-1 (bodyweight), administered orally in the diet, through biochemical and hematological analysis during the acute inflammatory reaction in Nile tilapia (Oreochromis niloticus), induced by Aeromonas hydrophila bacterins. The study used eighty tilapias, conditioned in 20 tanks (n=4), constituting the following treatments: T0 (control), T1 (2,25 mg zileuton) and T2 (4,50 mg zileuton), being sampled eight animals per treatment in three periods: 6, 24 and 48 hours post-inoculation, and a 10th group consisting of fish without any type of stimulus to obtain the reference values. In order to evaluate and determine the blood count and serum biochemical, it was necessary to collect blood samples. The hematology results of the tilapia treated with zileuton did not reveal alterations between tilapia subjected to different treatments and control fish (T0). The liver cytotoxicity analysis of tilapias treated with zileuton did not reveal significant (p≥0,05) alterations in AST and ALT serum enzymatic activity. The study of tilapia blood total protein showed decrease in the T1 group at 48 HPI. As the treatment time progressed, the results indicated decrease in the serum albumin levels for T2 group at 24 HPI. The determination of serum biochemichal of creatinine, cholesterol, triglycerides, and glucose did not differ statistically between treatments. The results observed in the hematological and biochemical analyzes allows to conclude that zileuton administered orally, at doses of 2,25 and 4,50 mg/Kg-1 (body weight) demonstrated to be clinically safe.(AU)
Asunto(s)
Animales , Aeromonas hydrophila , Cíclidos/sangre , Inhibidores de Proteína Activante de 5-Lipoxigenasa/administración & dosificación , Inflamación/tratamiento farmacológico , Hígado/fisiopatologíaRESUMEN
This study aimed to evaluate the clinical safety of doxycycline treatment (Sandoz Pharmacetical Industry from Brazil Ltd.), administered orally incorporated into the feed of Nile tilapia, Oreochromis niloticus. For this purpose, 75 Nile tilapia (±300g) from the same spawning were randomly distributed in 15 tanks (n=5), containing 100 L of water each, supplied with running water free from chlorine, to establish the following treatments: TO (Control - not treated with doxycycline); T1, T2, T3 and T4 (treated with 10, 20, 40 and 80mg of doxycycline/kg of body weight, respectively), in which 5 animals per treatment were sampled in 3 periods: 2, 4 and 8 days post-treatment (DPT). Blood samples were collected for hemogram determination and serum biochemical evaluation, as well as spleen, liver and kidneys (cranial and caudal) for somatic and histopathological evaluation. The results showed no significant difference among treatments in the serum values of creatinine, total protein, cholesterol, triglycerides, globulin, glycemia and alkaline phosphatase enzyme activity. However, serum levels of AST (aspartate aminotransferase) were significantly higher (P<0.05) in animals treated with 80 mg of doxycycline in the longest period of treatment (8 days). In the hematological evaluation of tilapia treated with doxycycline, no significant changes (P>0.05) were observed in erythrocyte counts, hematocrit, MCV, HCM and CHCM values. Doxycycline-treated tilapia did not present significant difference in the somatic analysis of spleen, liver and kidney when compared to control group. Therefore, the results demonstrated the clinical safety of oral treatment with doxycycline at doses of 10, 20, 40 and 80 mg/kg of b.w., although transient changes in liver functionality were observed after eight days of treatment with the dose of 80mg/kg.
Este estudo teve por objetivo avaliar a segurança clínica do tratamento com doxiciclina (Sandoz do Brasil Indústria Farmacêutica Ltda.), administrada via oral incorporada à ração em tilápias do Nilo, Oreochromis niloticus. Para tal, foram utilizadas 75 tilápias no Nilo (±300g) oriundas da mesma desova foram distribuídas aleatoriamente em 15 tanques (n=5), contendo 100 L de água cada, abastecidos com água corrente desprovida de cloro, para constituir os seguintes tratamentos: TO (Controle - não tratado com doxiciclina); T1, T2, T3 e T4 (tratados com 10, 20, 40 e 80mg de doxiciclina/kg de p.v., respectivamente. 5 animais por tratamento foram amostrados em 3 períodos: 2, 4 e 8 dias pós-tratamento (DPT). Foram coletadas amostras de sangue para determinação do hemograma e avaliação do bioquímico sérico, além de órgãos como baço, fígado e rins (cranial e caudal) para avaliação somática e histopatológica. Os resultados não mostraram diferença significativa entre os tratamentos nos valores séricos de creatinina, proteína total, colesterol, triglicerídeos, globulina, glicemia e atividade da enzima fosfatase alcalina. No entanto, os níveis séricos de AST (aspartato aminotransferase) foram significativamente maiores (P<0,05) nos animais tratados com 80 mg de doxiciclina no período mais longo de tratamento (8 dias). Na avaliação hematológica de tilápias tratadas com doxiciclina, não foram observadas alterações significativas (P>0,05) nas contagens de eritrocitos, valores de hematocrito, VCM, HCM e CHCM. Tilápias tratadas com doxiciclina não apresentaram diferença significativa na análise somática do baço, fígado e rim quando comparadas aos animais do grupo controle. Portanto, os resultados demonstraram a segurança clínica do tratamento oral com doxiciclina nas doses de 10, 20, 40 e 80 mg/kg de peso corporal, embora alterações transitórias na funcionalidade hepática tenham sido observadas após oito dias de tratamento com a dose de 80mg/kg.
Asunto(s)
Animales , Tetraciclinas , Doxiciclina/administración & dosificación , Cíclidos , Acuicultura/métodosRESUMEN
Lincomycin is a broad-spectrum antimicrobial acting against Gram-positive bacteria, widely used in veterinary medicine. In fish, there are only limited in vitro data, thus requiring the design of effective therapeutic protocols for their use in aquatic organisms. In this context, the objective was to evaluate the clinical safety of lincomycin treatment, administered orally in tilapia, through hematological, biochemical and somatic index evaluation. A total of 136 tilapia (+100g) were randomly distributed in 17 tanks (100L of water, n=8) to constitute the following treatments: TO (control group, not treated with lincomycin); T1, T2, T3 (treated with 10, 20 and 40mg/kg¹ of lincomycin b.w., respectively) and T4 physiological standard (reference values). Eight animals were sampled per treatment in 4 periods: 2, 4 and 8 days post-treatment (DPT), and a group that was treated for 8 days with the drug and then treated only with commercial feed until the 12th day (recovery period). Tilapia treated with lincomycin had no difference in the hematological and leukocyte evaluation, in the hepatic, renal and splenic somatic index. However, they presented a transient increase in the values of ALT, AST, cholesterol, triglycerides and creatinine, which returned to normal levels after the period of recovery (12DPT). Furthermore, an increase in total protein, albumin and globulin levels was observed in treated animals. It is concluded that although there were some transient changes during the experiment, lincomycin has a good clinical safety margin at doses of 10, 20 and 40mg/Kg¹ b.w. for Nile tilapia.
A lincomicina é um antimicrobiano de amplo espectro atuando contra bactérias gram-positivas, amplamente utilizada na medicina veterinária. Em peixes existem apenas dados limitados in-vitro, necessitando assim, de delineamento de protocolos terapêuticos eficazes para seu uso em organismos aquáticos. Desse modo, objetivou-se avaliar a segurança clínica do tratamento com lincomicina, administrada por via oral em tilápias, por meio da avaliação hematológica, bioquímica e indice somático hepático, renal e esplênico. Foram utilizadas 136 tilápias (±100g), distribuídas aleatoriamente em 17 tanques (100L de água, n=8) para constituir as repetições dos diferentes tratamentos: TO (grupo controle, não tratado com lincomicina); T1, T2, T3 (tratados com 10, 20 e 40mg/kg de p.v. de lincomicina, respectivamente) e T4 padrão fisiológico (valores de referência). Oito animais foram amostrados por tratamento em 4 períodos: 2, 4 e 8 dias pós-tratamento (DPT) com lincomicina, e um grupo que foi tratado por 8 dias com o fármaco e após isso tratado apenas com ração comercial até o 12º dia (período de recuperação). Tilápias tratadas com lincomicina não tiveram diferença na avaliação hematológica e leucocitária, no índice somático hepático, renal e esplênico, entretanto, apresentaram um aumento transitório nos valores de ALT, AST, colesterol, triglicérides e creatinina, que retornaram aos níveis normais após o período de recuperação (12DPT). Ademais, foram observados um incremento nos níveis de proteína total, albumina e globulina nos animais tratados. Conclui-se que embora tenha ocorrido algumas alterações transitórias ao decorrer do experimento, a lincomicina apresenta boa margem de segurança clinica nas doses de 10, 20 e 40mg/Kg¹ p.v para tilápia do Nilo.
Asunto(s)
Animales , Lincomicina/administración & dosificación , Tilapia/metabolismo , Antiinfecciosos/administración & dosificaciónRESUMEN
Little is known about the toxicity of immune modulators in fish. Zafirlukast is an anti-inflammatory that antagonizes cysteine leukotriene receptors (CysLTR1). Aiming to study immunomodulatory treatments on fish health, this study evaluated the clinical safety of oral zafirlukast treatment, through biochemical and hematological analyzes during acute inflammatory reaction in Nile tilapia (Oreochromis niloticus), induced by Aeromonas hydrophila bacterins. 72 young tilapias were randomly divided in 9 aquariums (100 L each, n=8) to compose the following treatments: T0 (control), T1 (Treatment with 250 µg zafirlukast) and T2 (Treatment with 500 µg zafirlukast). Eight animals were evaluated per treatment in three periods: six, 24 and 48 hours post-inoculation (HPI), blood collection was performed for hematological and serum biochemical evaluation. The study of hepatic and renal functionality revealed that treatment with both doses of zafirlukast did not result in changes in the circulating values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, triglycerides, cholesterol, and total protein, suggesting that the drug has not presented hepatotoxicity, as well as compromised liver and kidney functions. Tilapia submitted to treatment with 500 µg showed adverse hematological effects characterized by polycythemia associated with microcytosis. Therefore, oral treatment with zafirlukast has demonstrated clinical safety at a therapeutic dose of 250 µg in tilapia during acute aerocystitis, although hematological changes were observed in tilapia treated with overdose of this leukotriene blocker(AU)
Pouco se sabe sobre a toxicidade de imunomoduladores em peixes. Zafirlukast é um anti-inflamatório que antagoniza os receptores de leucotrienos cisteínicos (CysLTR1). Com o objetivo de estudar o efeito de tratamentos imunomoduladores sobre a saúde dos peixes, este estudo avaliou a segurança clínica do tratamento com zafirlucaste oral, por meio de análises bioquímicas e hematológicas durante reação inflamatória aguda em tilápia do Nilo (Oreochromis niloticus), induzida por bacterinas de Aeromonas hydrophila. Para tal, 72 tilápias jovens foram divididas aleatoriamente em 9 aquários (100 L cada, n=8) para compor os seguintes tratamentos: T0 (controle), T1 (Tratamento com 250 µg de zafirlucaste) e T2 (Tratamento com 500 µg de zafirlucaste). Oito animais foram avaliados por tratamento em três períodos: seis, 24 e 48 horas pós-inoculação (HPI), foi realizada coleta de sangue para avaliação hematológica e bioquímica sérica. O estudo da funcionalidade hepática e renal revelou que o tratamento com ambas as doses de zafirlucaste não resultou em alterações nos valores circulantes de aspartato aminotransferase (AST), alanina aminotransferase (ALT), fosfatase alcalina, creatinina, triglicerídeos, colesterol e proteína total, sugerindo que a droga não comprometeu as funções hepáticas e renais. As tilápias tratadas com 500 µg apresentaram efeitos hematológicos adversos caracterizados por policitemia associada a microcitose. Portanto, o tratamento oral com zafirlucaste demonstrou segurança clínica na dose de 250 µg em tilápias durante aerocistite aguda, embora alterações hematológicas tenham sido observadas em tilápias tratadas com sobredosagem deste bloqueador de leucotrieno.(AU)
Asunto(s)
Animales , Cíclidos , Antagonistas de Leucotrieno/administración & dosificación , Inflamación , HematologíaRESUMEN
This study aimed to evaluate the effect of astaxanthin on the hematological, biochemical and somatic response of Nile tilapia (Oreochromis niloticus) orally administered in the feed for a period of 60 days. For the study, 105 tilapia (n=35) from the same spawn were used, constituting the following treatments: Control = animals (not treated with astaxanthin); T100 and T200 = fish treated with 100 and 200 mg of astaxanthin/kg of feed, respectively. There were no hematological alterations in red blood cells counts, hematocrit, hemoglobin, MCV and MCHC. In addition, astaxanthin-fed tilapia presented a better thrombocyte and leukocyte responses with a marked decrease in the number of thrombocytes, lymphocytes and neutrophils. Among treatments, there were no changes in serum levels of total protein, albumin, globulins, aspartate aminotransferase and alkaline phosphate. Treatment with astaxanthin resulted in a decrease in triglyceride and glucose levels, as well as increase in hepatosomatic indices. The results of hematological and biochemical analyzes of tilapias demonstrated the clinical safety of this carotenoid, not causing harmful effects to the health of fish. Therefore, the antioxidant activity of this compound in tilapias resulted in an improvement in the leukocyte profile and contributed to hypolipidemic effects at the dose of 200mg of astaxanthin/kg of feed.(AU)
Objetivou-se avaliar o efeito da astaxantina na resposta hematológica, bioquímica e somática de tilápias do Nilo (Oreochromis niloticus) administrada via oral na ração por período de 60 dias. Para o estudo foram utilizadas 105 tilápias (n=35) oriundas da mesma desova, constituindo os seguintes tratamentos: Controle = animais (não tratados com astaxantina); T100= Animais tratados com 100mg de astaxantina/kg de ração; T200= Animais tratados com 200mg astaxantina/kg de ração. Não se observou alterações hematológicas na série vermelha (glóbulos vermelhos, hematócrito, hemoglobina, VCM e CHCM), além disso, apresentou melhor resposta trombocitária e leucocitária com marcada diminuição no número de linfócitos e neutrófilos. Não ocorreu alterações nos níveis séricos de proteína total, albumina, globulinas, aspartate aminotransferase e fostatase alcalina. O tratamento com astaxantina resultou em diminuição nos níveis de triglicerídeos, glicose e aumento nos índices hepatossomáticos. Portanto, os resultados das análises hematológicas e bioquímicas das tilápias demonstraram a segurança clínica desse carotenóide, não causando efeitos nocivos à saúde dos peixes. No entanto, a atividade antioxidante desse composto em tilápias resultou em melhora do perfil leucocitário e contribuiu para efeitos hipolipemiantes na dose de 200mg de astaxantina / kg de ração.(AU)
Asunto(s)
Animales , Cíclidos/sangre , Cíclidos/fisiología , Alimentos Fortificados/efectos adversos , Pruebas Hematológicas/veterinaria , Fenómenos BioquímicosRESUMEN
Little is known about the toxicity of immune modulators in fish. Zafirlukast is an anti-inflammatory that antagonizes cysteine leukotriene receptors (CysLTR1). Aiming to study immunomodulatory treatments on fish health, this study evaluated the clinical safety of oral zafirlukast treatment, through biochemical and hematological analyzes during acute inflammatory reaction in Nile tilapia (Oreochromis niloticus), induced by Aeromonas hydrophila bacterins. 72 young tilapias were randomly divided in 9 aquariums (100 L each, n=8) to compose the following treatments: T0 (control), T1 (Treatment with 250 µg zafirlukast) and T2 (Treatment with 500 µg zafirlukast). Eight animals were evaluated per treatment in three periods: six, 24 and 48 hours post-inoculation (HPI), blood collection was performed for hematological and serum biochemical evaluation. The study of hepatic and renal functionality revealed that treatment with both doses of zafirlukast did not result in changes in the circulating values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, triglycerides, cholesterol, and total protein, suggesting that the drug has not presented hepatotoxicity, as well as compromised liver and kidney functions. Tilapia submitted to treatment with 500 µg showed adverse hematological effects characterized by polycythemia associated with microcytosis. Therefore, oral treatment with zafirlukast has demonstrated clinical safety at a therapeutic dose of 250 µg in tilapia during acute aerocystitis, although hematological changes were observed in tilapia treated with overdose of this leukotriene blocker
Pouco se sabe sobre a toxicidade de imunomoduladores em peixes. Zafirlukast é um anti-inflamatório que antagoniza os receptores de leucotrienos cisteínicos (CysLTR1). Com o objetivo de estudar o efeito de tratamentos imunomoduladores sobre a saúde dos peixes, este estudo avaliou a segurança clínica do tratamento com zafirlucaste oral, por meio de análises bioquímicas e hematológicas durante reação inflamatória aguda em tilápia do Nilo (Oreochromis niloticus), induzida por bacterinas de Aeromonas hydrophila. Para tal, 72 tilápias jovens foram divididas aleatoriamente em 9 aquários (100 L cada, n=8) para compor os seguintes tratamentos: T0 (controle), T1 (Tratamento com 250 µg de zafirlucaste) e T2 (Tratamento com 500 µg de zafirlucaste). Oito animais foram avaliados por tratamento em três períodos: seis, 24 e 48 horas pós-inoculação (HPI), foi realizada coleta de sangue para avaliação hematológica e bioquímica sérica. O estudo da funcionalidade hepática e renal revelou que o tratamento com ambas as doses de zafirlucaste não resultou em alterações nos valores circulantes de aspartato aminotransferase (AST), alanina aminotransferase (ALT), fosfatase alcalina, creatinina, triglicerídeos, colesterol e proteína total, sugerindo que a droga não comprometeu as funções hepáticas e renais. As tilápias tratadas com 500 µg apresentaram efeitos hematológicos adversos caracterizados por policitemia associada a microcitose. Portanto, o tratamento oral com zafirlucaste demonstrou segurança clínica na dose de 250 µg em tilápias durante aerocistite aguda, embora alterações hematológicas tenham sido observadas em tilápias tratadas com sobredosagem deste bloqueador de leucotrieno.
Asunto(s)
Animales , Antagonistas de Leucotrieno/administración & dosificación , Cíclidos , Inflamación , HematologíaRESUMEN
This study aimed to evaluate the effect of astaxanthin on the hematological, biochemical and somatic response of Nile tilapia (Oreochromis niloticus) orally administered in the feed for a period of 60 days. For the study, 105 tilapia (n=35) from the same spawn were used, constituting the following treatments: Control = animals (not treated with astaxanthin); T100 and T200 = fish treated with 100 and 200 mg of astaxanthin/kg of feed, respectively. There were no hematological alterations in red blood cells counts, hematocrit, hemoglobin, MCV and MCHC. In addition, astaxanthin-fed tilapia presented a better thrombocyte and leukocyte responses with a marked decrease in the number of thrombocytes, lymphocytes and neutrophils. Among treatments, there were no changes in serum levels of total protein, albumin, globulins, aspartate aminotransferase and alkaline phosphate. Treatment with astaxanthin resulted in a decrease in triglyceride and glucose levels, as well as increase in hepatosomatic indices. The results of hematological and biochemical analyzes of tilapias demonstrated the clinical safety of this carotenoid, not causing harmful effects to the health of fish. Therefore, the antioxidant activity of this compound in tilapias resulted in an improvement in the leukocyte profile and contributed to hypolipidemic effects at the dose of 200mg of astaxanthin/kg of feed.
Objetivou-se avaliar o efeito da astaxantina na resposta hematológica, bioquímica e somática de tilápias do Nilo (Oreochromis niloticus) administrada via oral na ração por período de 60 dias. Para o estudo foram utilizadas 105 tilápias (n=35) oriundas da mesma desova, constituindo os seguintes tratamentos: Controle = animais (não tratados com astaxantina); T100= Animais tratados com 100mg de astaxantina/kg de ração; T200= Animais tratados com 200mg astaxantina/kg de ração. Não se observou alterações hematológicas na série vermelha (glóbulos vermelhos, hematócrito, hemoglobina, VCM e CHCM), além disso, apresentou melhor resposta trombocitária e leucocitária com marcada diminuição no número de linfócitos e neutrófilos. Não ocorreu alterações nos níveis séricos de proteína total, albumina, globulinas, aspartate aminotransferase e fostatase alcalina. O tratamento com astaxantina resultou em diminuição nos níveis de triglicerídeos, glicose e aumento nos índices hepatossomáticos. Portanto, os resultados das análises hematológicas e bioquímicas das tilápias demonstraram a segurança clínica desse carotenóide, não causando efeitos nocivos à saúde dos peixes. No entanto, a atividade antioxidante desse composto em tilápias resultou em melhora do perfil leucocitário e contribuiu para efeitos hipolipemiantes na dose de 200mg de astaxantina / kg de ração.
Asunto(s)
Animales , Alimentos Fortificados/efectos adversos , Cíclidos/fisiología , Cíclidos/sangre , Fenómenos Bioquímicos , Pruebas Hematológicas/veterinariaRESUMEN
Little is known about the toxicity of immune modulators in fish. Zafirlukast is an anti-inflammatory that antagonizes cysteine leukotriene receptors (CysLTR1). Aiming to study immunomodulatory treatments on fish health, this study evaluated the clinical safety of oral zafirlukast treatment, through biochemical and hematological analyzes during acute inflammatory reaction in Nile tilapia (Oreochromis niloticus), induced by Aeromonas hydrophila bacterins. 72 young tilapias were randomly divided in 9 aquariums (100 L each, n=8) to compose the following treatments: T0 (control), T1 (Treatment with 250 µg zafirlukast) and T2 (Treatment with 500 µg zafirlukast). Eight animals were evaluated per treatment in three periods: six, 24 and 48 hours post-inoculation (HPI), blood collection was performed for hematological and serum biochemical evaluation. The study of hepatic and renal functionality revealed that treatment with both doses of zafirlukast did not result in changes in the circulating values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, triglycerides, cholesterol, and total protein, suggesting that the drug has not presented hepatotoxicity, as well as compromised liver and kidney functions. Tilapia submitted to treatment with 500 µg showed adverse hematological effects characterized by polycythemia associated with microcyt
Little is known about the toxicity of immune modulators in fish. Zafirlukast is an anti-inflammatory that antagonizes cysteine leukotriene receptors (CysLTR1). Aiming to develop strategies for the sanitary management of fish farms, this study evaluated the clinical safety of oral zafirlukast treatment, through biochemical and hematological analyzes during acute inflammatory reaction in Nile tilapia (Oreochromis niloticus), induced by Aeromonas hydrophila bacterins. 72 young tilapias were randomly divided in 9 aquariums (100 L each, n=8) to compose the following treatments: T0 (control), T1 (Treatment with 250 µg zafirlukast) and T2 (Treatment with 500 µg zafirlukast). Eight animals were evaluated per treatment in three periods: six, 24 and 48 hours post-inoculation (HPI), blood collection was performed for hematological and serum biochemical evaluation. The study of hepatic and renal functionality revealed that treatment with both doses of zafirlukast did not result in changes in the circulating values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, triglycerides, cholesterol, and total protein, suggesting that the drug has not compromised liver and kidney functions. Tilapia submitted to treatment with 500 µg showed adverse hematological effects characterized by polycythemia associated with microcytosis and hypochromia. The
RESUMEN
This study aimed to evaluate the effect of astaxanthin on the hematological, biochemical and somatic response of Nile tilapia (Oreochromis niloticus) orally administered in the feed for a period of 60 days. For the study, 105 tilapia (n=35) from the same spawn were used, constituting the following treatments: Control = animals (not treated with astaxanthin); T100 and T200 = fish treated with 100 and 200 mg of astaxanthin/kg of feed, respectively. There were no hematological alterations in red blood cells counts, hematocrit, hemoglobin, MCV and MCHC. In addition, astaxanthin-fed tilapia presented a better thrombocyte and leukocyte responses with a marked decrease in the number of thrombocytes, lymphocytes and neutrophils. Among treatments, there were no changes in serum levels of total protein, albumin, globulins, aspartate aminotransferase and alkaline phosphate. Treatment with astaxanthin resulted in a decrease in triglyceride and glucose levels, as well as increase in hepatosomatic indices. The results of hematological and biochemical analyzes of tilapias demonstrated the clinical safety of this carotenoid, not causing harmful effects to the health of fish. Therefore, the antioxidant activity of this compound in tilapias resulted in an improvement in the leukocyte profile and contributed to hypolipidemic effects at the dose of 200mg of astaxanthin/kg of feed.
RESUMEN
Little is known about the toxicity of immune modulators in fish. Zafirlukast is an anti-inflammatory that antagonizes cysteine leukotriene receptors (CysLTR1). Aiming to study immunomodulatory treatments on fish health, this study evaluated the clinical safety of oral zafirlukast treatment, through biochemical and hematological analyzes during acute inflammatory reaction in Nile tilapia (Oreochromis niloticus), induced by Aeromonas hydrophilabacterins. 72 young tilapias were randomly divided in 9 aquariums (100 L each, n=8) to compose the following treatments: T0 (control), T1 (Treatment with 250 μg zafirlukast) and T2 (Treatment with 500 μg zafirlukast). Eight animals were evaluated per treatment in three periods: six, 24 and 48 hours post-inoculation (HPI), blood collection was performed for hematological and serum biochemical evaluation. The study of hepatic and renal functionality revealed that treatment with both doses of zafirlukast did not result in changes in the circulating values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, triglycerides, cholesterol, and total protein, suggesting that the drug has not presented hepatotoxicity, as well as compromised liver and kidney functions. Tilapia submitted to treatment with 500 μg showed adverse hematological effects characterizedby polycythemia associated with microcytosis. Therefore, oral treatment with zafirlukast has demonstrated clinical safety at a therapeutic dose of 250 μg in tilapia during acute aerocystitis, although hematological changes were observed in tilapia treatedwith overdose of this leukotriene blocker.
Pouco se sabe sobre a toxicidade de imunomoduladores em peixes. Zafirlukast é um anti-inflamatório que antagoniza os receptores de leucotrienos cisteínicos (CysLTR1). Com o objetivo de estudar o efeito de tratamentos imunomoduladores sobre a saúde dos peixes, este estudo avaliou a segurança clínica do tratamento com zafirlucaste oral, por meio de análises bioquímicas e hematológicas durante reação inflamatória aguda em tilápia do Nilo (Oreochromis niloticus), induzida por bacterinas de Aeromonas hydrophila.Para tal, 72 tilápias jovens foram divididas aleatoriamente em 9 aquários (100 L cada, n=8) para compor os seguintes tratamentos: T0 (controle), T1 (Tratamento com 250 μg de zafirlucaste) e T2 (Tratamento com 500 μg de zafirlucaste). Oito animais foram avaliados por tratamento em três períodos: seis, 24 e 48 horas pós-inoculação (HPI), foi realizada coleta de sangue para avaliação hematológica e bioquímica sérica. O estudo da funcionalidade hepática e renal revelou que o tratamento com ambas as doses de zafirlucaste não resultou em alterações nos valores circulantes de aspartato aminotransferase (AST), alanina aminotransferase (ALT), fosfatase alcalina, creatinina, triglicerídeos, colesterol e proteína total, sugerindo que a droga não comprometeu as funçõeshepáticas e renais. As tilápias tratadas com 500 μg apresentaram efeitos hematológicos adversos caracterizados por policitemia associada a microcitose. Portanto, o tratamento oral com zafirlucaste demonstrou segurança clínica nadose de 250 μg em tilápiasdurante aerocistite aguda, embora alterações hematológicas tenham sido observadas em tilápias tratadas com sobredosagem deste bloqueador de leucotrieno.
RESUMEN
The northern region of Brazil produces a large number of sheep, with Pará being the largest sheep breeding state in the region. In the Amazon region, livestock production is a challenge due to the high diversity of pathogens affecting humans and animals. Defensins are antimicrobial peptides acting as a first barrier against micro-organisms and present high variation in different organisms. The objective of this study was to detect polymorphisms in exon II in ß-defensin II in Amazon sheep. The gene was amplified by PCR from DNA extracted from 47 sheep blood samples from the Santa Inês breed. Products were sequenced, aligned and analyzed. Three single nucleotide polymorphism (SNP) positions were observed with transition substitutions (AâG) at positions 1643, 1659, and 1750. The 1643 and 1750 SNPs showed a low variability and significant deviations from Hardy-Weinberg equilibrium (HWE) (P < 0.05) meanwhile the SNP 1659 showed moderate absence of genetic variability and deviation from HWE (P > 0.05). Polymorphisms at 1643 and 1659 were predicted to modify amino acids in the peptide chain (isoleucine to valine and arginine to lysine, respectively) with no effects on protein function. Results from this study suggest that SNPs are important markers for ß-defensin II efficiency studies on the immune system of sheep in the Brazilian Amazon.
Asunto(s)
Polimorfismo de Nucleótido Simple/genética , beta-Defensinas/genética , Animales , Brasil , Femenino , Inmunidad Innata/genética , Inmunidad Innata/fisiología , Masculino , OvinosRESUMEN
Objetivou-se descrever os achados clínicos e ultrassonográficos de uma cabra leiteira apresentando mastite gangrenosa. Com a ultrassonografia convencional, observaram-se alterações consistentes com o avanço do quadro clínico, como alterações na ecogenicidade do leite e parênquima mamário. A ultrassonografia Doppler revelou aumento da velocidade de pico sistólico nos três momentos estudados, passando de 15 para 17 e 29cm/s. Houve redução, também, dos valores do índice de resistência, de 0,71 para 0,61 e 0,43. O índice de pulsatividade sofreu redução entre o segundo e o terceiro dia de observação, passando de 0,98 para 0,71. Foi possível estabelecer relação direta entre os achados ultrassonográficos e a gravidade da doença. A ultrassonografia convencional e Doppler podem ser utilizadas para o estudo hemodinâmico do úbere de cabras leiteiras, favorecendo diagnóstico e prognóstico de alterações nesse órgão.(AU)
Asunto(s)
Animales , Cabras/anomalías , Ultrasonografía Doppler/veterinaria , Ultrasonografía/veterinaria , Ecocardiografía/veterinaria , Mastitis/diagnóstico , Mastitis/veterinaria , Pronóstico , Glándulas Mamarias Animales/anomalías , Glándulas Mamarias AnimalesRESUMEN
Objetivou-se descrever os achados clínicos e ultrassonográficos de uma cabra leiteira apresentando mastite gangrenosa. Com a ultrassonografia convencional, observaram-se alterações consistentes com o avanço do quadro clínico, como alterações na ecogenicidade do leite e parênquima mamário. A ultrassonografia Doppler revelou aumento da velocidade de pico sistólico nos três momentos estudados, passando de 15 para 17 e 29cm/s. Houve redução, também, dos valores do índice de resistência, de 0,71 para 0,61 e 0,43. O índice de pulsatividade sofreu redução entre o segundo e o terceiro dia de observação, passando de 0,98 para 0,71. Foi possível estabelecer relação direta entre os achados ultrassonográficos e a gravidade da doença. A ultrassonografia convencional e Doppler podem ser utilizadas para o estudo hemodinâmico do úbere de cabras leiteiras, favorecendo diagnóstico e prognóstico de alterações nesse órgão...
Asunto(s)
Animales , Cabras/anomalías , Ecocardiografía/veterinaria , Mastitis/diagnóstico , Ultrasonografía Doppler/veterinaria , Ultrasonografía/veterinaria , Glándulas Mamarias Animales/anomalías , Glándulas Mamarias Animales , Mastitis/veterinaria , PronósticoRESUMEN
5-Lipoxygenase (5-LO) metabolites are important pro-inflammatory lipid mediators. However, much still remains to be understood about the role of such mediators in bone remodeling. This study aimed to investigate the effect of 5-LO metabolites, LTB4 and CysLTs, in a model of mechanical loading-induced bone remodeling. Strain-induced tooth movement and consequently alveolar bone resorption/apposition was achieved by using a coil spring placed on molar and attached to incisors of C57BL6 (wild-type-WT), 5-LO deficient mice (5-LO(-/-)) and mice treated with 5-LO inhibitor (zileuton-ZN) or with antagonist of CysLTs receptor (montelukast-MT). The amount of bone resorption and the number of osteoclasts were determined morphometrically. The expression of inflammatory and bone remodeling markers in periodontium was analyzed by qPCR. Osteoclast differentiation and TNF-α production were evaluated in vitro using RAW 264.7 cells treated with LTB4 or LTD4. Bone resorption, TRAP(+) cells and expression of Tnfa, Il10 and Runx2 were significantly diminished in 5-LO(-/-), ZN- and MT-treated mice. The expression of Rank was also reduced in 5-LO(-/-) and MT-treated mice. Accordingly, LTB4 and LTD4 in association with RANKL promoted osteoclast differentiation and increased TNF-α release in vitro. These data demonstrate that the absence of 5-LO metabolites, LTB4 and CysLTs reduces osteoclast recruitment and differentiation, consequently diminishing bone resorption induced by mechanical loading. Thus, 5-LO might be a potential target for controlling bone resorption in physiological and pathological conditions.
Asunto(s)
Araquidonato 5-Lipooxigenasa/metabolismo , Resorción Ósea/metabolismo , Leucotrienos/metabolismo , Osteoclastos/metabolismo , Animales , Diferenciación Celular/fisiología , Línea Celular , Ensayo de Inmunoadsorción Enzimática , Leucotrieno B4/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Osteoclastos/citología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Estrés MecánicoRESUMEN
Identification of the nucleotide consensus sequence in mammalian replication origins is a difficult and controversial problem. The hypothesis that local DNA topology could be involved in recognition by replication proteins is an exciting possibility. Secondary DNA structures, including intrinsically bent DNA, can be easily detected, and they may indicate a specific pattern in or near mammalian replication origins. This work presents the entire mapping of the intrinsically bent DNA sites (IBDSs), using in silico analysis and a circular permutation assay, of the DNA replication origins oriGNAI3, oriC, oriB, and oriA in the mammalian amplified AMPD2 gene domain. The results show that each origin presents an IBDS that flanks the straight core of these DNA replication sites. In addition, the in silico prediction of the nucleosome positioning reveals a strong indication that the center of an IBDS is localized in a nucleosome-free region (NFR). The structure of each of these curved sites is presented together with their helical parameters and topology. Together, the data that we present here indicate that the oriGNAI3 origin where preferential firing to the replication initiation events in the amplified AMPD2 domain occurs is the only origin that presents a straight, narrow region that is flanked on both sides by two intrinsically bent DNA sites within a short distance (~300 bp); however, all of the origins present at least one IBDS, which is localized in the NFR region. These results indicate that structural features could be implicated in the mammalian DNA replication origin and support the possibility of detecting and characterizing these segments.
Asunto(s)
AMP Desaminasa/genética , ADN/química , AMP Desaminasa/metabolismo , Animales , Secuencia de Bases , ADN/metabolismo , Sitios Genéticos , Datos de Secuencia Molecular , Regiones Promotoras Genéticas , Origen de Réplica/genéticaRESUMEN
The aim of this study was to evaluate the reproductive performance of ewes during the dry and wet months in northern Brazil. The females were divided into two groups: reproduced during the dry season and lambing in the rainy season (Group A, n = 38), and the opposite with the other group (Group B, n = 55). There was no difference (P > 0.05) for expression of estrus (86.8 and 98.3%), pregnancy rate (86.8 and 90.9%), lambing (76.3 and 83.6%), abortion (9 and 7.4%), fecundity (86.8 and 96.3%), birth (103.4 and 110.8%) and prolificacy (113.7 and 115.2%) observed in groups A and B, respectively. However, there was a difference (P < 0.05) in lamb mortality (26.6% for group A and 49% for group B). Ewes from group A presented a higher average live weight at the end of the reproductive season and during the final third of pregnancy (P < 0.05).
Asunto(s)
Clima , Reproducción/fisiología , Sequías , OvinosRESUMEN
The aim of this study was to evaluate the reproductive performance of ewes during the dry and wet months in northern Brazil. The females were divided into two groups: reproduced during the dry season and lambing in the rainy season (Group A, n = 38), and the opposite with the other group (Group B, n = 55). There was no difference (P > 0.05) for expression of estrus (86.8 and 98.3%), pregnancy rate (86.8 and 90.9%), lambing (76.3 and 83.6%), abortion (9 and 7.4%), fecundity (86.8 and 96.3%), birth (103.4 and 110.8%) and prolificacy (113.7 and 115.2%) observed in groups A and B, respectively. However, there was a difference (P < 0.05) in lamb mortality (26.6% for group A and 49% for group B). Ewes from group A presented a higher average live weight at the end of the reproductive season and during the final third of pregnancy (P < 0.05).(AU)
Asunto(s)
Reproducción/fisiología , Clima , Sequías , OvinosRESUMEN
Seventy-seven ewes were randomly divided into groups according to parturition season and suckling mode [Rainy season: continuous (n=14) and controlled (n=13); Dry season: continuous (n=25) and controlled (n=25)]. The controlled suckling mode, in both seasons, resulted in a decrease in variables, intervals between parturition and first estrus (reduction of 27.11 and 11.46 days for rainy and dry season, respectively; P<0.05) and between parturition and estrus of conception (reduction of 12.81 and 13.58 days, for rainy and dry season, respectively; P<0.05). As to the lambs, the weight gain was higher in animals subjected to controlled suckling in relation to continuous, especially when lambing occurred in the rainy season (17.83±0.56 vs. 13.95±0.52kg for Lambs' weight at 90 days old, respectively; P<0.05). Therefore, it was concluded that controlled suckling management is better indicated for the Amazonian region, since it allows the ewes to have a shorter puerperium period and the lambs exhibit higher weight gain.
Foram utilizadas 77 ovelhas, divididas aleatoriamente em grupos de acordo com o período de parição e o manejo de amamentação [chuvoso: contínua (n=14) e controlada (n=13); seco: contínua (n=25) e controlada (n=13)]. O sistema de amamentação controlado, em ambos os períodos, resultou em decréscimo para as variáveis intervalos entre parto e primeiro estro (redução de 27,11 e 11,46 dias para os períodos chuvoso e seco, respectivamente; P<0,05) e entre parto e estro da concepção (redução de 12,81 e 13,58 dia para os períodos chuvoso e seco, respectivamente; P<0,05). Quanto ao desempenho ponderal dos cordeiros, o ganho de peso foi maior para os animais submetidos ao regime de amamentação controlada em relação à contínua, especialmente quando os nascimentos ocorreram no período chuvoso (17,83±0,56 vs. 13,95±0,52kg para o peso dos cordeiros aos 90 dias de idade, respectivamente; P<0,05). Contudo, o manejo de amamentação controlada é indicado para a região amazônica, por permitir menor tempo de puerpério das ovelhas e maior ganho de peso dos cordeiros.